Fri, Aug 2, 11:13 AM (88 days ago)
On August 2, 2024, Zymeworks Inc. entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) to facilitate the sale of its common stock. This agreement allows Zymeworks to sell shares through TD Cowen as its sales agent, with sales being conducted as "at the market offerings" on Nasdaq or other trading markets. TD Cowen will receive a commission of up to 3% of the gross sales proceeds. The agreement includes standard indemnification and contribution rights and can be terminated by either party with written notice. The shares are being offered under Zymeworks' Registration Statement on Form S-3ASR. This move provides Zymeworks with a flexible method to raise capital as needed.